All News

back, LBP, spine, AS

Finding Spondylitis Among Psoriasis, Uveitis and Colitis Patients

Jack Cush, MD

Maksymowych and colleagues have shown that screening patients with either psoriasis, iritis, or colitis may yield a surprising percentage meeting ASAS criterial for axial spondyloarthritis (axSpA).

Read Article
NSAIDs.pills_.caps_.jpg

NSAIDs Used Despite Contraindications

EurekAlert!

Osteoarthritis affects 600 million people worldwide, making it a leading cause of disability.

Read Article
RheumNow Podcast square

Best Rheumatologists (7.19.2024)

Jack Cush, MD

This week on the RheumNow Podcast, Dr. Jack Cush reviews the news and journal reports of interesting, including irAE, pollution and Psoriasis, microwave therapy, scleroderma without scleroderma that only the best rheumatologists could discern.

Read Article
scleroderma,month,organ,heart

Systemic sclerosis sine scleroderma

Jack Cush, MD

Systemic sclerosis sine scleroderma (ssSSc), which accounts for nearly 10% of systemic sclerosis (SSc) patients and was first described in 1962, is a subset of SSc.

Read Article
JAK Janus

New indications for JAK inhibitors

Janet Pope, MD, MPH, FRCPC

There are several new positive RCTs for JAK inhibitors. Here is a summary of trials and new indications for JAKi in GCA, pediatrics, GI, dermatology and more.

Read Article
abdominal-pain-2821941_640.jpg

Inflammatory bowel disease in spondyloarthritis - does it matter?

Antoni Chan, MD, PhD

Do the clinical features of axSpA patients with and without IBD differ?

In Abstract OP0085 at #EULAR2024, De Hooge M et al presented data from the METEOR cohort that identify clinical differences between these two groups. This will be important in order to stratify the management approach in axSpA patients with or without IBD as the emerging therapies have different effects on EMMs.

Read Article
podcast logo

"Don't You Know Who I am?" (5.17.2024)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from the past 2 weeks. This week's question: can we prevent gout, ILD or psoriasis?

Read Article
RheumNow Podcast square

Featured BSR Abstracts (5.2.2024)

Jack Cush, MD

Dr. Jack Cush muses on the news, journal reports, FDA announcements and the 2024 BSR abstracts just released.

Read Article
RheumNow Podcast square

Ides of March (3.15.2024)

Jack Cush, MD

Dr. Jack Cush has advice for Caesar and the superstitious, and covers pregnancy, platelets, dialysis and vaccinations in Lupus.

Read Article
NEW VIEWPOINT—Arthritis complicating inflammatory bowel disease—the future is now https://t.co/FyojGF6Pvx @DrLauraCoates #GITwitter https://t.co/kMewGTDQTc

Links:

The Lancet Rheumatology TheLancetRheum ( View Tweet)
Pathogenesis of Autoimmune Liver Disease (ALDs) ALDs, including autoimmune hepatitis (AIH), primary biliary cholangitis (PBC), and primary sclerosing cholangitis (PSC), are complex conditions involving the liver's immune-mediated damage https://t.co/acgwwglKve https://t.co/ZDpF1VhBlc

Links:

Dr. John Cush RheumNow ( View Tweet)
Review of Amyloidosis The New England Journal of Medicine has published a review of systemic amyloidosis. https://t.co/4507N4DwLk https://t.co/Q0MP5XXUHr

Links:

Dr. John Cush RheumNow ( View Tweet)
FDA has approved risankizumab (Skyrizi) to treat adults with moderately to severely active ulcerative colitis (UC), making it the IL-23 inhibitor approved for UC. Approval is based on two large phase 3 clinical trials (COMMAND, INSPIRE) https://t.co/wNSZdWWDO1 https://t.co/mlwxIrdUD2

Links:

Dr. John Cush RheumNow ( View Tweet)
SpA patients with IBD, compared to those without IBD, were less frequently male and more frequently HLA-B27 negative, had higher rates of uveitis and lower rates of psoriasis, exhibited more structural damage on SI joints in the METEOR cohort #EULAR2024 OP0085 @RheumNow https://t.co/c2KdzIumc4

Links:

Dr. Antoni Chan synovialjoints ( View Tweet)
Research presented at DDW 2024 demonstrated the superiority of guselkumab over ustekinumab or placebo in 1,021 patients with moderately to severely active Crohn's disease enrolled in the phase III GALAXI 2 and GALAXI 3 trials https://t.co/HdZf24Twsq https://t.co/REeAAskpX5

Links:

Dr. John Cush RheumNow ( View Tweet)
Cohort study 243 671total joint arthroplasty pts finds found no association of preoperative or postoperative colonoscopy with Periop Jt Infx risk w/ 1-yr F/U. PJI risk was incr by comorbidity (diabetes, kidney disease, and pulmonary disease). https://t.co/0J8F9YN2l2 https://t.co/USoplPPHh3

Links:

Dr. John Cush RheumNow ( View Tweet)
Endoscopy and Worry are indicated in the face of DYSPEPSIA and any of these: @BCryer https://t.co/6TabKhiLPO
Dr. John Cush RheumNow ( View Tweet)
Testing for H. Pylori. Serologic tests are OK but after Rx eradication, 25% of pts will remain positive for H. Pylori. @BCryer

Dr. John Cush RheumNow ( View Tweet)

Multiple Rx options to treat H. Pylori - Dr. Cryer recs regimens of 14ds; top line w/ bismuth is most recommended. (most effective is the one the patient will actualy take!) @BCryer https://t.co/f6836Ga1Fz
Dr. John Cush RheumNow ( View Tweet)
H. Pylori is usually acquired during childhood, remains dormant until activated years later. Is assoc w/ PUD and gastric cancer, not dyspepsia. Baylor Univ Grand Round By Dr. Byron Cryer @BCryer https://t.co/KXZfigVYX9
Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×